Print Page      Close Window     

Investors

SEC Filings

6-K
OBSEVA SA filed this Form 6-K on 03/30/2018
Entire Document
 


LOGO

 

Results: Efficacy Secondary endpoints: Individual D3 and D5      D3D5 Nolasiban Nolasiban PlaceboDeltapPlaceboDeltap 900 mg900 mg n194194196194 Ongoing pregnancy22.2%25.3%3.1%0.47734.7%45.9%11.2%0.034* rate at 10 weeks Clinical pregnancy rate* at 6 weeks22.7%27.3%4.6%0.29035.7%47.4%11.7%0.022 Positive pregnancy 33.5%35.6%2.1%0.66645.9%54.6%8.7%0.112 test at 14 days * Nolasiban increases the relative ongoing pregnancy rate by 32% following single embryo transfer at Day5